| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS205455 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts45 |
| Applications： | Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 6754, was isolated from the IHD-W strain of Vaccinia by S. Dales. Not described in the original publication, it is presumed to have been selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. The non-permissive incubation temperature is 39.5°C. This mutant was not assigned to a Dales EM category. Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This conditional lethal mutant, originally designated plaque isolate no. 6754, was isolated from the IHD-W strain of Vaccinia by S. Dales. Not described in the original publication, it is presumed to have been selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. The non-permissive incubation temperature is 39.5°C. This mutant was not assigned to a Dales EM category. Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Effect on Host： | CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2002: Dulbeccos Modified Eagles Medium (DMEM) Fetal Bovine Serum |
| Recommended Host： | Recommended Host: xa0BSC-40 (ATCC CRL-2761) Production host: BSC-40 (ATCC CRL-2761)
Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2 |
| Name of Depositor： | S. Dales, R. Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Vaccinia virus ts mutant |
|---|---|
| 商品货号： | TS205455 |
| Classification： | Poxviridae, Orthopoxvirus |
| Agent： | Vaccinia virus ts mutant |
| Strain： | IHD-W Dts45 |
| Applications： | Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This conditional lethal mutant, originally designated plaque isolate no. 6754, was isolated from the IHD-W strain of Vaccinia by S. Dales. Not described in the original publication, it is presumed to have been selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. The non-permissive incubation temperature is 39.5°C. This mutant was not assigned to a Dales EM category. Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This conditional lethal mutant, originally designated plaque isolate no. 6754, was isolated from the IHD-W strain of Vaccinia by S. Dales. Not described in the original publication, it is presumed to have been selected after mutagenesis with nitrosoguanidine and replication in the presence of bromodeoxyuridine. The non-permissive incubation temperature is 39.5°C. This mutant was not assigned to a Dales EM category. Mutations were located by complementation analysis (Lackner, et al, 2003) within vaccinia map locations A30 and G(6-8). Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses. |
| Effect on Host： | CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium： | ATCC® Medium 30-2002: Dulbeccos Modified Eagles Medium (DMEM) Fetal Bovine Serum |
| Recommended Host： | Recommended Host: xa0BSC-40 (ATCC CRL-2761) Production host: BSC-40 (ATCC CRL-2761)
Alternate hosts: MRC-5, BSC-1, HeLa, LLC-MK2 |
| Name of Depositor： | S. Dales, R. Condit |
| References： | Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807 Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570 Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746 Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |
